Boston Scientific Corporation and Penumbra, Inc., announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion. "Penumbra is a w…
Under the ownership and leadership of CEO Jimmy St. Louis, Agentis Longevity has completed the acquisition of Arete Wellness, the performance-driven health platform founded by Adam Bobo and Van Hunt, uniting two leaders in longevity medicine and human optimization under a shared mission to help people live healthier, …
Rakuten Medical, Inc. and LOTTE Biologics announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmuno…
TetraScience, the Scientific Data and AI company, announced a collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, with a goal of accelerating AI across biopharma R&D and manufacturing by transforming scientific data into AI-native form and developing intelligent workflows at scal…
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology platforms, announced that it has entered into a multi-target antibody discovery collaboration with Link Cell Therapies. This collaboration will leverage Nona's proprietary fully human HCAb Harbour Mice…
CytoReason, a leader in AI-powered computational disease modeling, announced the expansion of its collaboration with Sanofi for the third time. This multi-year agreement, valued at up to $16 million, further solidifies their partnership. CytoReason technology enables researchers to extract insights from molecular and…
Veeva Systems and BioMarin Pharmaceutical Inc. announced a long-term enterprise agreement that builds upon their long-standing relationship. The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leverag…
MediLink Therapeutics announced that it has entered into a new collaboration and exclusive licensing agreement with Roche for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types. Under the terms of the agreement,…
Eli Lilly and Company and Ventyx Biosciences, Inc. , a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipeline of…
Helix, the leading enterprise genomics company, announced a multi-year strategic collaboration with GSK, the global biopharma company. This agreement provides GSK access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. Helix GenoSphere™ cohorts consist o…
Page 18 of 36